1. Ascherio, A., et al.: Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA286(24), 3083–3088 (2001)

   Article  Google Scholar 

2. Barrat, F., et al.: In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med.195(5), 603–613 (2002)

   Article  Google Scholar 

3. Beccuti, M., et al.: GPU accelerated analysis of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. In: Mencagli, G., et al. (eds.) Euro-Par 2018. LNCS, vol. 11339, pp. 626–637. Springer, Cham (2019).https://doi.org/10.1007/978-3-030-10549-5_49

   Chapter  Google Scholar 

4. Bhalla, A., Amento, E., Glimcher, B.S.L.: 1,25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. J. Immunol.133(4), 1748–1754 (1984)

   Google Scholar 

5. Bielekova, B., Becker, B.L.: Monoclonal antibodies in MS: mechanisms of action. Neurology74(Suppl 1), 31–40 (2010)

   Article  Google Scholar 

6. Bielekova, B., et al.: Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2R\(\alpha \)-targeted therapy (daclizumab) in multiple sclerosis. Proc. Natl. Acad. Sci. USA103(15), 5941–5946 (2006)

   Article  Google Scholar 

7. Bielekova, B., et al.: Intrathecal effects of daclizumab treatment of multiple sclerosis. Neurology77(21), 1877–1886 (2011)

   Article  Google Scholar 

8. Chiacchio, F., Pennisi, M., Russo, G., Motta, S., Pappalardo, F.: Agent-based modeling of the immune system: NetLogo, a promising framework. BioMed Res. Int.2014, 907171 (2014)

   Article  Google Scholar 

9. Chimeh, M.K., Richmond, P., Heywood, P., Pennisi, M., Pappalardo, F.: Parallelisation strategies for agent based simulation of immune systems. BMC Bioinform.20(Suppl 6), 1–14 (2019).https://doi.org/10.1186/s12859-019-3181-y

   Article  Google Scholar 

10. Gold, R., et al.: Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial. Lancet381, 2167–75 (2013)

    Article  Google Scholar 

11. Godin, D.: The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One4(2), e4565 (2009)

    Article  Google Scholar 

12. Gorman, S., et al.: Topically applied 1,25-Dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J. Immunol.179(9), 6273–6283 (2007)

    Article  Google Scholar 

13. Gregori, S., Casorati, M., Amuchastegui, S., Smiroldo, S., Davalli, A., Adorini, L.: Regulatory T cells induced by 1 alpha, 25-Dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J. Immunol.167(4), 1945–1953 (2001)

    Article  Google Scholar 

14. Lim, J.A., et al.: New feasible treatment for refractory autoimmune encephalitis: low-dose interleukin-2. J. Neuroimmunol.299, 107–111 (2016)

    Article  Google Scholar 

15. Luessi, F., Engel, S., Spreer, A., Bittner, S., Zipp, F.: GFAP\(\alpha \) IgG-associated encephalitis upon daclizumab treatment of MS. Neurol. Neuroimmunol. Neuroinflamm.5(5), e481 (2018)

    Article  Google Scholar 

16. Martin, R., McFarland, H.F., McFarlin, D.E.: Immunological aspects of demyelinating diseases. Ann. Rev. Immunol.10, 153–187 (2003)

    Article  Google Scholar 

17. Pappalardo, F., Pennisi, M., Rajput, A.M., Chiacchio, F., Motta, S.: Relapsing-remitting multiple scleroris and the role of vitamin D : an agent based model. In: ACM-BCB, pp. 744–748 (2014)

    Google Scholar 

18. Penna, G., et al.: Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory t cells by 1,25-dihydroxyvitamin D3. Blood106(10), 3490–3497 (2005)

    Article  Google Scholar 

19. Pennisi, M., Rajput, A.M., Toldo, L., Pappalardo, F.: Agent based modeling of Treg-Teff cross regulation in relapsing-remitting multiple sclerosis. BMC Bioinf.14(Suppl 16), S9 (2013)

    Article  Google Scholar 

20. Pennisi, M., Russo, G., Motta, S., Pappalardo, F.: Agent based modeling of the effects of potential treatments over the blood-brain barrier in multiple sclerosis. J. Immunol. Methods427, 6–12 (2015)

    Article  Google Scholar 

21. Ponsonby, A., et al.: Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA293(4), 463–469 (2005)

    Article  Google Scholar 

22. Sospedra, M., Martin, R.: Immunology of multiple sclerosis. Annu. Rev. Immunol.23, 683–747 (2005)

    Article  Google Scholar 

23. Sundström, P., et al.: An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology62, 2277–2282 (2004)

    Article  Google Scholar 

24. Vélez de Mendizábal, N., et al.: Modeling the effector - regulatory T cell cross-regulation reveals the intrinsic character of relapses in multiple sclerosis. BMC Syst. Biol.5(1), 1–15 (2011)

    Article  Google Scholar 

25. Wilensky, U.: NetLogo, Center for connected learning and computer-based modeling, Northwestern University, Evanston, IL (1999).http://ccl.northwestern.edu/netlogo/

26. Wuest, S.C., et al.: A role for interleukin-2 transpresentation in dendritic cellmediated T cell activation in humans, as revealed by daclizumab therapy. Nat. Med.17(5), 604–609 (2011)

    Article  Google Scholar 

Download references